Buck joined ClearCut after more than twenty-five years of successfully developing and commercializing innovative medical technologies. Prior to joining ClearCut, Buck served as CEO or held other senior leadership roles spanning cardiac rhythm management, structural heart disease, and minimally invasive surgery segments, with companies including Johnson & Johnson, St. Jude Medical, and most recently, Mardil Medical. He brings a proven track record of successfully developing and commercializing a number of breakthrough technologies that have dramatically improved healthcare for patients.
Buck holds a master of management from Northwestern University's Kellogg Graduate School of management and a bachelor's degree from Indiana University.
"ClearCut's success to date has been driven by an incredibly strong team. As we prepare for commercialization, we are happy to be adding world class senior talent who will lay the foundation for our future success. Jim's experience developing and commercializing innovative technologies makes for a perfect fit with ClearCut,” said chairman Mike Berman. "His proven ability to build value in venture-backed companies and navigate regulatory, reimbursement, and early market commercialization environments will be an invaluable asset."
"ClearCut's ClearSight System is poised to make a major impact on cancer surgery and clinical pathology," noted Buck. "The team has done a phenomenal job developing, protecting, and clinically testing this important breakthrough in MRI technology form factor, and in establishing strong clinical and strategic relationships that will be the basis for global adoption starting with the European launch late this year. It is exciting to join such a dynamic team."